Drug Profile
NNC 0113 2023
Alternative Names: NN9023; NNC0113-2023; OG2023SCLatest Information Update: 12 Nov 2019
Price :
$50
*
At a glance
- Originator Novo Nordisk
- Class Antihyperglycaemics
- Mechanism of Action Glucagon-like peptide 1 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 30 Sep 2019 Discontinued - Phase-I for Type 2 diabetes mellitus (In volunteers) in USA (PO) in the third quarter of 2019
- 05 Dec 2018 Novo Nordisk completes a phase I trial in Type-2 diabetes mellitus (In volunteers) in USA (PO) (NCT03617081)
- 09 Aug 2018 Phase-I clinical trials in Type-2 diabetes mellitus (In volunteers) in USA (PO) (NCT03617081)